# An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet

> **NCT05462535** · — · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 4785 (actual)

## Conditions studied

- Hypertension,Essential

## Interventions

- **DRUG:** Amosartan Plus Tab.

## Key facts

- **NCT ID:** NCT05462535
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2021-07-15
- **Final completion:** 2021-07-15
- **Target enrollment:** 4785 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462535, "An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05462535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*